Hypoxia-Inducible Factors Activate CD133 Promoter through ETS Family Transcription Factors

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Ohnishi, Shunsuke ^a   Maehara, Osamu ^b   Nakagawa, Koji ^b   Kameya, Ayano ^b   Otaki, Kanako ^b   Fujita, Hirotoshi ^b   Higashi, Ryosuke ^b   Takagi, Kikuko ^a   Asaka, Masahiro ^a   Sakamoto, Naoya ^a   Kobayashi, Masanobu ^c   Takeda, Hiroshi ^b  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c HEALTH SCIENCES UNIVERSITY OF HOKKAIDO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD133 ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; TRANSCRIPTION FACTOR ELK 1; TRANSCRIPTION FACTOR ETS; TRANSCRIPTION FACTOR ETS 1;

ARTICLE; BINDING SITE; CANCER CELL; CHROMATIN IMMUNOPRECIPITATION; COLON CANCER; CONTROLLED STUDY; EMBRYO; GENE DELETION; GENE MUTATION; HUMAN; HUMAN CELL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM;

ANTIGENS, CD; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BINDING SITES; CELL HYPOXIA; CELL LINE, TUMOR; ETS-DOMAIN PROTEIN ELK-1; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GLYCOPROTEINS; HEK293 CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; PEPTIDES; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEIN C-ETS-1; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84879274254     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066255     Document Type: Article

References (34)

1. Visvader JE, Lindeman GJ, (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8: 755-768.
2. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. (2004) Identification of human brain tumour initiating cells. Nature 432: 396-401.
3. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ, (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951.
4. Yin S, Li J, Hu C, Chen X, Yao M, et al. (2007) CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120: 1444-1450.
5. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, et al. (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1: 313-323.
6. O'Brien CA, Pollett A, Gallinger S, Dick JE, (2007) A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 445: 106-110.
7. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, et al. (2007) Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111-115.
8. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, et al. (1997) A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90: 5013-5021.
9. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, et al. (1997) AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90: 5002-5012.
10. Shmelkov SV, Jun L, St Clair R, McGarrigle D, Derderian CA, et al. (2004) Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood 103: 2055-2061.
11. Tabu K, Sasai K, Kimura T, Wang L, Aoyanagi E, et al. (2008) Promoter hypomethylation regulates CD133 expression in human gliomas. Cell Res 18: 1037-1046.
12. Yi JM, Tsai HC, Glöckner SC, Lin S, Ohm JE, et al. (2008) Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res 68: 8094-8103.
13. Semenza GL, (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732.
14. Rasheed S, Harris AL, Tekkis PP, Turley H, Silver A, et al. (2009) Hypoxia-inducible factor-1alpha and-2alpha are expressed in most rectal cancers but only hypoxia-inducible factor-1alpha is associated with prognosis. Br J Cancer 100: 1666-1673.
15. Baba Y, Nosho K, Shima K, Irahara N, Chan AT, et al. (2010) HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol 176: 2292-2301.
16. Wang GL, Jiang BH, Rue EA, Semenza GL, (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 92: 5510-5514.
17. Loboda A, Jozkowicz A, Dulak J, (2010) HIF-1 and HIF-2 transcription factors- Similar but not identical. Mol Cells 29: 435-442.
18. Heddleston J, Li Z, Lathia J, Bao S, Hjelmeland A, et al. (2010) Hypoxia inducible factors in cancer stem cells. Br J Cancer 102: 789-795.
19. Soeda A, Park M, Lee D, Mintz A, Androutsellis-Theotokis A, et al. (2009) Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene 28: 3949-3959.
20. Iida H, Suzuki M, Goitsuka R, Ueno H, (2012) Hypoxia induces CD133 expression in human lung cancer cells by up-regulation of OCT3/4 and SOX2. Int J Oncol 40: 71-79.
21. Tabu K, Kimura T, Sasai K, Wang L, Bizen N, et al. (2010) Analysis of an alternative human CD133 promoter reveals the implication of Ras/ERK pathway in tumor stem-like hallmarks. Mol Cancer 9: 39.
22. Fisher RJ, Mavrothalassitis G, Kondoh A, Papas TS, (1991) High-affinity DNA-protein interactions of the cellular ETS1 protein: the determination of the ETS binding motif. Oncogene 6: 2249-2254.
23. Sharrocks AD, (2001) The ETS-domain transcription factor family. Nat Rev Mol Cell Biol 2: 827-837.
24. Wollenick K, Hu J, Kristiansen G, Schraml P, Rehrauer H, et al. (2012) Synthetic transactivation screening reveals ETV4 as broad coactivator of hypoxia-inducible factor signaling. Nucleic Acids Res 40: 1928-1943.
25. Le Bras A, Lionneton F, Mattot V, Lelièvre E, Caetano B, et al. (2007) HIF-2alpha specifically activates the VE-cadherin promoter independently of hypoxia and in synergy with Ets-1 through two essential ETS-binding sites. Oncogene 26: 7480-7489.
26. Elvert G, Kappel A, Heidenreich R, Englmeier U, Lanz S, et al. (2003) Cooperative interaction of hypoxia-inducible factor-2alpha (HIF-2alpha) and Ets-1 in the transcriptional activation of vascular endothelial growth factor receptor-2 (Flk-1). J Biol Chem 278: 7520-7530.
27. Aprelikova O, Wood M, Tackett S, Chandramouli GV, Barrett JC, (2006) Role of ETS transcription factors in the hypoxia-inducible factor-2 target gene selection. Cancer Res 66: 5641-5647.
28. Matsumoto K, Arao T, Tanaka K, Kaneda H, Kudo K, et al. (2009) mTOR signal and hypoxia-inducible factor-1 alpha regulate CD133 expression in cancer cells. Cancer Res 69: 7160-7164.
29. Harris AL, (2002) Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47.
30. Mylonis I, Chachami G, Samiotaki M, Panayotou G, Paraskeva E, et al. (2006) Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1alpha. J Biol Chem 281: 33095-33106.
31. Karapetsas A, Giannakakis A, Pavlaki M, Panayiotidis M, Sandaltzopoulos R, et al. (2011) Biochemical and molecular analysis of the interaction between ERK2 MAP kinase and hypoxia inducible factor-1α. Int J Biochem Cell Biol 43: 1582-1590.
32. Hashimoto O, Shimizu K, Semba S, Chiba S, Ku Y, et al. (2011) Hypoxia induces tumor aggressiveness and the expansion of CD133-positive cells in a hypoxia-inducible factor-1α-dependent manner in pancreatic cancer cells. Pathobiology 78: 181-192.
33. Sun C, Song H, Zhang H, Hou C, Zhai T, et al. (2012) CD133 expression in renal cell carcinoma (RCC) is correlated with nuclear hypoxia-inducing factor 1α (HIF-1α). J Cancer Res Clin Oncol.
34. Schwab LP, Peacock DL, Majumdar D, Ingels JF, Jensen LC, et al. (2012) Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Breast Cancer Res 14: R6.